本资产评估报告依据中国资产评估准则编制 四川金石亚洲医药股份有限公司拟对合并海南亚洲 制药股份有限公司形成的商誉进行减值测试所涉及 的资产组组合可回收价值 东洲评报字【2024】第 1004 号 （报告书及附件） 共 1 册 第 1 册 上海东洲资产评估有限公司 2024 年 4 月 8 日 资产评估报告 中国资产评估协会 资产评估业务报告备案回执 | 报告编码： | 3131020001202401037 | | --- | --- | | 合同编号： | 东洲评委（202402054）号 | | 报告类型： | 法定评估业务资产评估报告 | | 报告文号： | 东洲评报字【2024】第1004号 | | 报告名称： | 四川金石亚洲医药股份有限公司拟对合并海南亚洲 制药股份有限公司形成的商誉进行减值测试所涉及 | | | 的资产组组合可回收价值资产评估报告 | | 评估结论： | 1,907,000,000.00元 | | 评估报告日： | 2024年04月08日 | | 评估机构名称： | 上海东洲资产评估有限公司 | | 签名人员： | 李雨勤 （资产评估师） 会员编号：24120011 | | | ...

证券代码：300434 证券简称：金石亚药 公告编号：2024-010 四川金石亚洲医药股份有限公司 关于聘任证券事务代表的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 四川金石亚洲医药股份有限公司（以下简称"公司"）于 2024 年 4 月 24 日 召开第五届董事会第三次会议，审议通过了《关于聘任证券事务代表的议案》。 同意聘任王莹女士（简历见附件）为公司证券事务代表，与公司证券事务代表何 欣女士共同协助董事会秘书履行职责，任期与公司本届董事会任期一致。 王莹女士已参加深圳证券交易所组织的上市公司董事会秘书任前培训，并取 得上市公司董事会秘书培训证明，具备与其行使职权相应的任职条件，不存在《深 圳证券交易所创业板股票上市规则》、《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》规定的不得担任上市公司证券事务代表的情形。 公司证券事务代表王莹女士联系方式如下： 联系电话：028-87086807 传真：028-87086861 电子信箱：goldstone@goldstone-group.com 特此公告。 附件：王莹女士简历 ...

证券代码：300434 证券简称：金石亚药 公告编号：2024-001 四川金石亚洲医药股份有限公司 第五届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 表决结果：11 票同意，0 票反对，0 票弃权，本议案获得通过。 2、审议通过《2023 年度董事会工作报告》 《2023 年度董事会工作报告》具体内容详见同日刊登在巨潮资讯网 （www.cninfo.com.cn）上的相关公告。 公司现任独立董事钟鹏、贾佑龙、刘初旺、赵小微和离任独立董事马文杰、 汪立荔、朱建伟、缪建泉分别向董事会提交了《2023 年度独立董事述职报告》， 并将在 2023 年年度股东大会上进行述职；上述报告的具体内容详见同日刊登在 巨潮资讯网（www.cninfo.com.cn）上的相关公告。 本议案尚需提交公司 2023 年年度股东大会审议。 表决结果：11 票同意，0 票反对，0 票弃权，本议案获得通过。 3、审议通过《2023 年度财务决算报告》 1 四川金石亚洲医药股份有限公司（以下简称"公司"）第五届董事会第三次 会议于 202 ...

Financial Performance - The company's revenue for Q1 2024 was ¥362,785,115.79, a decrease of 13.58% compared to ¥419,787,729.70 in the same period last year[4] - Net profit attributable to shareholders was ¥89,816,224.68, down 37.39% from ¥143,460,482.45 year-on-year[4] - Basic and diluted earnings per share decreased by 37.38% to ¥0.2236 from ¥0.3571 in the same quarter last year[4] - The net profit for Q1 2024 was CNY 89,543,650.31, a decrease of 37.1% compared to CNY 142,497,992.18 in Q1 2023[15] - Operating profit for Q1 2024 was CNY 115,048,924.11, down from CNY 184,249,348.46 in the same period last year, reflecting a decline of 37.6%[15] - Total revenue from sales in Q1 2024 was CNY 221,959,957.20, compared to CNY 350,792,078.64 in Q1 2023, indicating a decrease of 36.6%[17] - The total comprehensive income for Q1 2024 was CNY 89,543,650.31, compared to CNY 142,497,992.18 in Q1 2023, reflecting a decrease of 37.1%[16] Cash Flow and Assets - The net cash flow from operating activities was -¥90,480,979.33, representing a decline of 56.84% compared to -¥57,691,400.00 in the previous year[4] - Cash and cash equivalents decreased to CNY 444,143,577.19 from CNY 545,898,926.96, reflecting a decline of 18.5%[11] - The cash flow from operating activities for Q1 2024 was negative CNY 90,480,979.33, worsening from negative CNY 57,691,400.00 in Q1 2023[19] - The total current assets decreased to CNY 1,344,736,190.86 from CNY 1,371,587,670.56, a decline of 2.0%[12] - Total non-current assets increased to CNY 1,760,658,774.68 from CNY 1,729,850,994.45, an increase of 1.8%[12] Equity and Liabilities - Total assets at the end of the reporting period were ¥3,105,394,965.54, a slight increase of 0.13% from ¥3,101,438,665.01 at the end of the previous year[4] - Shareholders' equity attributable to the parent company increased by 3.74% to ¥2,490,245,750.15 from ¥2,400,429,525.47[4] - Total liabilities decreased to CNY 591,785,286.41 from CNY 677,372,636.19, a reduction of 12.6%[13] - The total equity attributable to shareholders increased to CNY 2,490,245,750.15 from CNY 2,400,429,525.47, an increase of 3.7%[13] Operating Costs and Expenses - The total operating costs for the current period amount to CNY 247,274,368.45, an increase of 4.4% from CNY 236,336,112.04 in the previous period[14] - Research and development expenses decreased to CNY 8,503,028.08 in Q1 2024 from CNY 17,587,226.51 in Q1 2023, a reduction of 51.6%[15] - The company incurred financial expenses of CNY -1,432,158.76 in Q1 2024, compared to CNY -627,377.47 in Q1 2023, indicating an increase in financial costs[15] Market and Operational Insights - The overall market demand for cold medicine products stabilized in Q1 2024, contributing to the decline in revenue and profit[7] - The company experienced a decrease in sales prepayments, impacting the net cash flow from operating activities[7] - The company reported non-recurring gains of ¥2,172,349.82 during the quarter, including government subsidies and other income[5] - The company reported a significant reduction in employee compensation payable, decreasing to CNY 33,896,086.08 from CNY 75,786,697.07, a decline of 55.3%[13] - Inventory decreased to CNY 225,394,191.50 from CNY 238,164,264.61, a decrease of 5.2%[12] - Accounts receivable increased to CNY 100,957,025.89 from CNY 79,477,350.02, representing a growth of 27.1%[11]

Financial Performance - The company's total revenue for 2023 was approximately ¥1.21 billion, a decrease of 2.69% compared to ¥1.24 billion in 2022[30]. - Net profit attributable to shareholders was approximately ¥126.20 million, down 42.32% from ¥218.79 million in the previous year[30]. - The basic earnings per share decreased to ¥0.31, a decline of 42.59% from ¥0.54 in 2022[30]. - Operating cash flow net amount was approximately ¥151.14 million, down 53.21% from ¥323.04 million in 2022[30]. - Total assets at the end of 2023 were approximately ¥3.10 billion, an increase of 1.36% from ¥3.06 billion at the end of 2022[30]. - Net assets attributable to shareholders increased by 5.55% to approximately ¥2.40 billion from ¥2.27 billion in 2022[30]. - The company reported a significant decline in quarterly net profit, with a loss of approximately ¥12.58 million in Q4 2023[32]. - The company reported a non-operating income of CNY 12.09 million in 2023, down from CNY 23.03 million in 2022[36]. - The company received government subsidies amounting to CNY 7.9 million in 2023, compared to CNY 11.65 million in 2022[36]. - The company reported a total revenue of 8,327 million for the year, maintaining the same figure as the previous period[113]. Market Position and Competition - The company reported a significant reliance on its main products, with the sales revenue from the Kuaike cold medicine series accounting for a high percentage of total operating income and gross profit[6]. - The company is facing increasing competition in the domestic market due to rising health awareness and potential entry of foreign pharmaceutical companies[4]. - The OTC market for cold medicine is significant, with an estimated 1.043 billion people in China suffering from colds annually, indicating a strong demand for self-medication products[41]. - The health food market in China is projected to grow from CNY 211.3 billion in 2022 to CNY 286.7 billion by 2027, with a compound annual growth rate of 6.3%[42]. - The Chinese herbal medicine industry is expected to reach a market size of CNY 8 trillion by 2030, with an annual growth rate of 10.3% from 2016 to 2030[43]. Research and Development - The company has a diverse R&D pipeline, including integrated raw material drug formulations and calcium mineral series products, but faces risks related to drug development and approval processes[7]. - The company plans to expand its product line and enhance R&D capabilities in new composite pipeline technologies[30]. - The company is actively pursuing several R&D projects, including the consistency evaluation of diclofenac sodium sustained-release tablets, aimed at enhancing product competitiveness[66]. - The total R&D investment in 2023 was ¥50,011,112.66, representing 4.14% of operating revenue, an increase from 3.15% in 2022[70]. - The company is committed to research and development, although specific figures or projects were not disclosed in the report[116]. Quality Control and Compliance - The company has implemented strict quality control measures, exceeding national standards, but still faces risks related to product quality and potential economic losses[7]. - The company acknowledges the impact of national policies on the pharmaceutical industry, including price control measures that may affect profit margins[8]. - The company has no significant discrepancies between financial reports prepared under international and Chinese accounting standards[33][34]. - The company has implemented various internal control systems to enhance operational efficiency and risk management[151]. - The company has established a clear internal control system with defined roles and responsibilities to mitigate risks[152]. Strategic Initiatives - The company plans to distribute cash dividends of 1.10 RMB per 10 shares to all shareholders, based on a total of 401,743,872.00 RMB[9]. - The company has initiated significant investment projects, such as the Jinxi raw material drug project, which carries risks if not successfully completed[7]. - The company is focusing on market expansion strategies to improve overall performance in the upcoming fiscal year[30]. - The company aims to enhance brand loyalty and influence among future consumer groups through targeted marketing strategies[53]. - The company is committed to a marketing-driven approach to overcome current growth bottlenecks, utilizing a diverse product cluster strategy to balance commercial risks and expand market share[96]. Environmental Responsibility - The company adheres to various environmental protection laws and standards, ensuring compliance in its operations[162]. - The company has established a monitoring system for wastewater discharge, ensuring compliance with environmental regulations[170]. - The company has implemented a new strategy for wastewater treatment, focusing on reducing nitrogen and phosphorus pollution[170]. - The company has engaged third-party monitoring for pollutant emissions as part of its environmental compliance strategy[180]. - The company has committed to achieving carbon peak and carbon neutrality goals through structured environmental responsibility[181]. Governance and Management - The company has established a transparent performance evaluation and incentive mechanism for senior management, ensuring compliance with legal standards[106]. - The company held its first temporary shareholders' meeting on December 22, 2023, electing the fifth board of directors, which consists of 11 members, including 4 independent directors[103]. - The company has maintained compliance with governance standards, ensuring effective internal control and decision-making processes throughout the reporting period[102]. - The company has a governance structure in place with a mix of executive and independent directors, ensuring diverse oversight[113]. - The company has established a commitment to ensure that its shareholders, directors, supervisors, and senior management do not operate or assist in any competing business during their tenure[200].

2023 年度监事会工作报告 2023 年，四川金石亚洲医药股份有限公司（以下简称"公司"）监事会，从 切实维护公司利益和广大股东权益出发，严格依照《公司法》、《证券法》等法律 法规，以及《公司章程》、《监事会议事规则》的有关规定，认真履行和独立行使 监事会的监督职权和职责。公司监事通过参加监事会会议、列席董事会会议、与 公司董事及高级管理人员沟通交流、检查公司各项工作报告和财务报告等形式， 对公司的生产经营、重大事项、财务状况、内部控制、信息披露、关联交易以及 董事、高级管理人员履行职责等方面进行了有效的审查和监督，较好地保障了公 司股东权益、公司利益和员工的合法权益，促进了公司的规范化运作。现将 2023 年度监事会主要工作汇报如下： 四川金石亚洲医药股份有限公司 报告期内，在公司全体股东的大力支持下，在董事会和管理层的积极配合下， 监事列席了董事会和股东大会会议，参与公司重大决策的讨论，依法监督各次董 事会和股东大会的议案和会议召开程序。 一、2023 年度监事会工作情况 报告期内，公司共召开监事会会议 6 次，全体监事均亲自出席会议，不存在 缺席会议的情况。监事会会议的召集、召开程序符合《公司法》、《 ...

关于四川金石亚洲医药股份有限公司 非经营性资金占用及其他关联 资金往来情况的专项报告 二○二三年度 关于四川金石亚洲医药股份有限公司 非经营性资金占用及其他关联资金往来情况 的专项报告 信会师报字[2024]第 ZD10063 号 四川金石亚洲医药股份有限公司全体股东： 我们审计了四川金石亚洲医药股份有限公司(以下简称"金石亚 药")2023 年度的财务报表，包括 2023 年 12 月 31 日的合并及母公司 资产负债表、2023 年度合并及母公司利润表、合并及母公司现金流量 表、合并及母公司所有者权益变动表和相关财务报表附注，并于 2024 年 4 月 24 日出具了报告号为信会师报字[2024]第 ZD10061 号的无保 留意见审计报告。 金石亚药管理层根据中国证券监督管理委员会《上市公司监管指 引第 8 号——上市公司资金往来、对外担保的监管要求》（证监会公 告〔2022〕26 号）和《深圳证券交易所创业板上市公司自律监管指南 第 1 号——业务办理》的相关规定编制了后附的 2023 年度非经营性 资金占用及其他关联资金往来情况汇总表（以下简称"汇总表"）。 编制汇总表并确保其真实、准确、完整是金石 ...

（汪立荔） 作为四川金石亚洲医药股份有限公司（以下简称"公司"）的独立董事，在 2023 年度工作中，本人严格按照《公司法》、《上市公司独立董事管理办法》、 《深圳证券交易所创业板股票上市规则》、《深圳证券交易所上市公司自律监管 指引第 2 号—创业板上市公司规范运作》以及《公司章程》、《公司独立董事工 作制度》等法律、法规、部门规章和规范性文件及公司规章制度的有关规定，独 立、勤勉地履行职责，有效发挥独立董事的作用，较好地维护了公司整体利益及 全体股东的合法权益。现将 2023 年度工作情况述职如下： 一、独立董事的基本情况 四川金石亚洲医药股份有限公司 2023 年度独立董事述职报告 (一)个人基本情况及工作履历 汪立荔，女，1977 年出生，本科学历，注册会计师。现任中审众环会计师 事务所（特殊普通合伙）上海自贸试验区分所合伙人，2017 年 10 月至 2023 年 12 月担任四川金石亚洲医药股份有限公司独立董事。 (二)关于独立性的情况说明 本人具备《上市公司独立董事管理办法》所要求的独立性，不存在影响独立 性的情况。 二、独立董事年度履职概况 (一)出席股东大会及董事会情况 2023 年度，公司 ...

四川金石亚洲医药股份有限公司 2023 年度董事会工作报告 2023 年度，四川金石亚洲医药股份有限公司（以下简称"公司"）董事会 严格按照《公司法》、《证券法》、《深圳证券交易所创业板股票上市规则》等 法律、法规和《公司章程》、《股东大会议事规则》、《董事会议事规则》等公 司制度的规定，切实履行股东大会赋予的董事会职责，规范有效地开展董事会各 项工作，严格执行股东大会各项决议，认真落实董事会的各项决议。公司全体董 事均依照相关法律、法规和《公司章程》赋予的权利和义务，恪尽职守、勤勉尽 责，保证董事会科学决策和规范运作，保障股东权益、公司利益和员工的合法权 益。现将 2023 年度董事会主要工作汇报如下： 一、2023 年经营情况回顾及说明 2023 年度，公司实现营业收入 120,919.94 万元，同比下降 2.69%；实现归属 于上市公司股东的净利润为 12,619.97 万元，同比下降 42.32 %；实现归属于公司 股东的扣除非经常性损益的净利润 11,411.32 万元，同比下降 41.71%。截至 2023 年 12 月 31 日，公司资产总额 310,143.87 万元，较上年末增长 1.36 ...

2023 年度独立董事述职报告 （贾佑龙） 本人贾佑龙，自 2023 年 12 月 22 日经四川金石亚洲医药股份有限公司（以 下简称"公司"）2023 年第一次临时股东大会选举为公司独立董事。作为公司 独立董事，本人严格按照《公司法》、《上市公司独立董事管理办法》、《深圳 证券交易所创业板股票上市规则》、《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》以及《公司章程》、《公司独立董事工作制度》 等法律、法规、部门规章和规范性文件及公司规章制度的有关规定，独立、勤勉 地履行职责，有效发挥独立董事的作用。现将 2023 年度工作情况述职如下： 一、独立董事的基本情况 (一)个人基本情况及工作履历 四川金石亚洲医药股份有限公司 贾佑龙，男，1963 年 8 月出生。上海财经大学研究生毕业，经济学硕士。 曾在中投证券有限公司、长江承销保荐有限公司、甬兴证券有限公司从事投资银 行业务工作多年，服务多家公司改制、重组、上市及后续资本运作工作，2023 年 8 月退休，2023 年 12 月至今担任四川金石亚洲医药股份有限公司独立董事。 (二)关于独立性的情况说明 本人具备《上市公司独立董事管理办 ...